Nuklearmedizin-nuclear Medicine最新文献

{"title":"Longterm Survial after Re-challenge with Radiumdichlorid - a Case Report.","authors":"Bilêl Habacha, Xiao Wei, Florian C Gärtner, Jörg Ellinger, Ralph A Bundschuh, Markus Essler","doi":"10.1055/a-1345-3150","DOIUrl":"https://doi.org/10.1055/a-1345-3150","url":null,"abstract":"The life-prolonging effects of Radium223-dichlorid (RaCl2) have been shown in the ALSYMCA trial in 2013 [1] in patients with advanced prostate cancer and dominating bone metastases. Consequently, it was approved by the US Food and Drug Administration (FDA) as well as the European Medicines Agency (EMA). Typical initial treatment consists of 6 cycles RaCl2 given in intervals of 4 weeks. As often relapse of the disease can be observed in the treated patients after some time, soon the repeated application of RaCl2 was discussed and analyzed in prospective trials [2]. While toxicity of repeated application of RaCl2 was found to be acceptable and no major issue in most cases, the outcome was shown to be very variable. Therefore, we want to report on one patient in whom bone metastases of an advanced, castration-resistant prostate carcinoma could be stabilized for nearly two years with repeated treatment with RaCl2.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"60 4","pages":"299-301"},"PeriodicalIF":1.5,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25385176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Doxorubicin-Induced Cardiomyopathy by 99mTc-3PRGD2 Scintigraphy Targeting Integrin αvβ3 in a Rat Model.","authors":"Shi Sui,&nbsp;Yang Hou","doi":"10.1055/a-1331-7138","DOIUrl":"https://doi.org/10.1055/a-1331-7138","url":null,"abstract":"<p><p>The present study evaluated interstitial alterations in doxorubicin-induced cardiomyopathy using a radiolabeled RGD peptide ^99mTc-3PRGD2 specific for integrin αvβ3 that targets myofibroblasts.Cardiomyopathy was induced in 20 Sprague-Dawley rats by intraperitoneal doxorubicin injections (2.5 mg/kg/week) for up to six weeks. ^99mTc-3PRGD2 scintigraphy was performed in control rats (n = 6) at baseline and three, six, and nine weeks after first doxorubicin administration (n = 6, 6, and 5 for each time point). For another three rats of 6-week modeling, cold c(RGDyK) was co-injected with ^99mTc-3PRGD2 to evaluate specific radiotracer binding. Semi-quantitative parameters were acquired to compare radiotracer uptake among all groups. The biodistribution of ^99mTc-3PRGD2 was evaluated by a γ-counter after scintigraphy. Haematoxylin and eosin, and Masson's staining were used to evaluate myocardial injury and fibrosis, while western blotting and immunofluorescence co-localization were used to analyze integrin αvβ3 expression in the myocardium.The ^99mTc-3PRGD2 half-life in the cardiac region (Heart<i>t</i> _1/2) of the 9-week model and heart radioactivity percentage (%Heart_20 min, %Heart_40 min and %Heart_60 min) of the 6 and 9-week models were significantly increased compared to the control. Heart-to-background ratio (HBR_20 min, HBR_40 min and HBR_60 min) increase began in the third week, continued until the sixth week, and was reversed in the ninth week, which paralleled the changing trend of cardiac integrin αvβ3 expression. The myocardial biodistribution of ^99mTc-3PRGD2 was significantly correlated with integrin β3 expression.The ^99mTc-3PRGD2 scintigraphy allows for non-invasive visualization of interstitial alterations during doxorubicin-induced cardiomyopathy.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"60 4","pages":"289-298"},"PeriodicalIF":1.5,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25417414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ausbildung in Nuklearmedizin und Zukunftsperspektiven.","authors":"Siroos Mirzaei,&nbsp;John O Prior,&nbsp;Mohsen Farsad,&nbsp;Rainer W Lipp,&nbsp;Roland Hustinx","doi":"10.1055/a-1486-5876","DOIUrl":"https://doi.org/10.1055/a-1486-5876","url":null,"abstract":"We read with the greatest interest the editorial by Carrio et al [1] and would like to express our full support for the idea of strengthening Nuclear Medicine as a clinical specialty. With the introduction and the emerging application of molecular imaging by PET/ CT and increasing development and application of different radionuclides in the treatment of various oncological entities, Nuclear Medicine has become an indispensable part of oncological management in many tumor patients [2]. The radionuclide therapy of neuroendocrine tumors, bone metastases, recurrent disease in thyroid cancer, and prostate cancer are some examples of established theranostics in our specialty. This requires, however, thorough basic knowledge of various tumors and of other oncological therapy modalities, as well as risk assessment and management of possible side effects. Prostate cancer is the third most common cancer in the USA [3]. Later on this year 2021, we are eagerly looking forward for the publication of the phase 3 VISION trial [4]. Patients with metastatic prostate cancer with PSMA positive scans were randomized in a 2:1 ratio to receive either 177Lu-PSMA-617 plus best supportive/best standard of care or to receive best supportive/best standard of care only. Primary end points of this study are overall survival and progression free survival based on radiology results. In case of a positive outcome this will tremendously boost therapy numbers in nuclear medicine centers and will require additional well trained nuclear medicine physicians and nuclear medicine technicians in the near future. Recent studies have reported the potential involvement of nuclear medicine in the management of patients affected by COVID-19 [5, 6]. On the other side, the COVID-19 pandemic also affected medical staff in some clinical departments in Europe. Therefore, we decided to provide assistance to other departments in our hospital with our staff (S.M.). The young residents and young specialists perform night guard in the pulmonary disease department and in the emergency department. Assistance in the oncology department will also be considered in the future. The physicians from Nuclear Medicine are assigned as residents and can contact senior physicians in the department in case of any uncertainties. This fruitful collaboration will also continue in the future. With this kind of cooperation, clinical needs for probably less common nuclear medicine investigations can also be identified earlier and appropriate adaptations, especially local ones, can be made. In the past, we have continued to offer investigations in our portfolio, which were no longer relevant in clinical routine use, such as radionuclide ventriculography; on the other hand, we have lost investigations in some centers, that could be used even longer, such as renal 99mTc-DMSA scan or quantitative lymphography of the extremities, or therapy of bone metastases with 153Sm. These regional losses were in part due to a lack of kn","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"60 4","pages":"264-265"},"PeriodicalIF":1.5,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39257574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NuklearMedizin 2021 – „digital reloaded“.","authors":"","doi":"10.1055/a-1529-3765","DOIUrl":"https://doi.org/10.1055/a-1529-3765","url":null,"abstract":"Vom 14. bis zum 17. April fand die „NuklearMedizin 2021 – digital“, die 59. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin, erneut als Online-Kongress statt. Nachdem wir in einem parallelen Planungsansatz zunächst auch die „Hybrid“-Variante mit lokalen Satellitenveranstaltungen verfolgt hatten, machte uns die Pandemie erneut einen dicken Strich durch die Rechnung. Gemeinsam mit Prof. Dr. Ken Hermann als Geschäftsführer der nmi GmbH und seinem Team, der Veranstaltungsorganisation von der vokativ GmbH sowie einer Task Force des DGN-Vorstands wurden alle Hebel in Gang gesetzt, um das digitale Format des Kongresses trotzdem – oder gerade erst recht – weiterzuentwickeln. Das scheint uns gemeinsam gelungen zu sein.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"60 4","pages":"305"},"PeriodicalIF":1.5,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39257575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DGN und nmi – nun mit eigenem Personal.","authors":"","doi":"10.1055/a-1539-8817","DOIUrl":"https://doi.org/10.1055/a-1539-8817","url":null,"abstract":"Er war im Jahr 2019 Leiter des wissenschaftlichen Komitees und im Jahr 2020 Kongresspräsident der DGN-Jahrestagung. Aufgrund dieser Ämter hat er dem DGN-Vorstand bereits von 2018–2020 angehört. In den vergangenen Jahren hat sich Herr Professor Essler besonders für die Weiterentwicklung und das „Reimbursement“ von innovativen nuklearmedizinischen Therapieverfahren wie der SIRT und der 177Lu-PSMA-Therapie engagiert.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"60 4","pages":"308-309"},"PeriodicalIF":1.5,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39257577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avoidance of iodine deficiency/excess during pregnancy in Hashimoto's thyroiditis.","authors":"Lutz van Heek,&nbsp;Christiane Staudacher,&nbsp;Michael Faust,&nbsp;Costanza Chiapponi,&nbsp;Jasmin Mettler,&nbsp;Matthias Schmidt,&nbsp;Alexander Drzezga,&nbsp;Markus Dietlein,&nbsp;Carsten Kobe","doi":"10.1055/a-1400-3522","DOIUrl":"https://doi.org/10.1055/a-1400-3522","url":null,"abstract":"<p><strong>Purpose: </strong> Hashimoto's thyroiditis is a common disease that also affects pregnant women. We analyzed to what extent the inflammatory process of Hashimoto's thyroiditis changes with iodine prophylaxis in pregnant women. The target for immunologic activity was levels of thyroid antibodies (TPO).</p><p><strong>Methods: </strong> The data were collected retrospectively from 20 consecutive, pregnant patients who had been diagnosed with Hashimoto's thyroiditis between 01.12.2012 and 01.12.2014 and had received iodine supplementation with 100 µg (n = 1) or 150 µg (n = 19). At least two measurements of TPO antibody levels taken during pregnancy and one after pregnancy were evaluated for each patient in the study group.</p><p><strong>Results: </strong> At the end of pregnancy, the average TPO antibody level for the 20 patients studied was 137 IU/ml (+/-214 IU/ml), the lowest being 16 IU/ml and the highest 1000 IU/ml. Despite iodine prophylaxis, levels of TPO antibodies decreased in 18 patients during pregnancy, falling below the reference value of 35 IU/ml in 5 cases. However, in one patient TPO antibodies increased from 60 IU/ml to 237 IU/ml during pregnancy while in another, levels remained constant at 1000 IU/ml.</p><p><strong>Conclusion: </strong> Iodine prophylaxis in pregnant women, taken at a dose of 100 or 150 μg daily was shown to have no negative systemic effects on Hashimoto's thyroiditis in a group of pregnant women with increased TPO levels, and can therefore be recommended for expectant mothers, including those with this disease.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"60 4","pages":"266-271"},"PeriodicalIF":1.5,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25510610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intracranial 131I-chTNT Brachytherapy in Patients with Deep-Seated Glioma: A Single-center Experience with 10-Year Follow-up from China.","authors":"Ming Zhao,&nbsp;Xiangping Fu,&nbsp;Zhiwen Zhang,&nbsp;Anmin Li,&nbsp;Xiaopeng Wang,&nbsp;Xuexiu Li","doi":"10.1055/a-1429-1967","DOIUrl":"https://doi.org/10.1055/a-1429-1967","url":null,"abstract":"<p><strong>Objective: </strong> The intracranial brachytherapy has been applied for decades, however, no results with long-term follow-up have been reported. This study investigated the long-term efficiency of intra-tumoral injection of ¹³¹I-chTNT in patients with deep-seated glioma.</p><p><strong>Method: </strong> Thirty-five patients undergoing ¹³¹I-chTNT brachytherapy between December 2004 and May 2009 were enrolled. ¹³¹I-chTNT was injected at a dose of 1.5 mCi/cm³ at an interval of 1 month for consecutive 3 times. Serial ECT scan and MRI were performed during follow-up. Progression-free survival (PFS) and overall survival (OS) were analyzed. Adverse reactions were graded with WHO Toxicity Grading Scale for determining the severity of adverse events.</p><p><strong>Results: </strong> ECT scan showed that enhanced accumulation of radioactive agents in the tumor lasted for more than 30 days. Three months after final injection, tumor complete remission (CR) was observed in 4 patients (11.4 %), partial remission (PR) in 11 cases (31.4 %), stable disease (SD) in 10 cases (28.6 %) and progressive disease (PD) in 10 cases (28.6 %). At 6-month, CR, PR, SD and PD were 2, 6, 12 and 15 respectively. After 10 years of follow-up, median progression-free survival (PFS) and overall survival (OS) were 5.4 and 11.4 months. One-year survival was 45.7 %, two and five-year survival was 8.6 %, ten-year survival was 5.7 %. Multivariate analysis showed that pathological grade and tumor diameter were independent prognostic factors for PFS and OS. Grade I-II adverse events occurred after drug injection, including nausea, fever, headache, hairloss and fatigue.</p><p><strong>Conclusion: </strong> ¹³¹I-chTNT intracranial brachytherapy is efficient and safe for patients with deep-seated glioma. It is a reliable option for inoperable glioma patients.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"60 4","pages":"283-288"},"PeriodicalIF":1.5,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25575348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Fireside chat \"§ 13 (2b) AMG in nuclear medicine therapy\" - a follow-up event of NuklearMedizin 2020 - Digital].","authors":"Marianne Patt,&nbsp;Frank Bengel,&nbsp;Markus Essler,&nbsp;Bernd-Joachim Krause,&nbsp;Torsten Kuwert,&nbsp;Kambiz Rahbar,&nbsp;Osama Sabri,&nbsp;Wolfgang Schäfer,&nbsp;Matthias Schreckenberger,&nbsp;Wolfgang A Weber,&nbsp;Ken Herrmann","doi":"10.1055/a-1489-0375","DOIUrl":"https://doi.org/10.1055/a-1489-0375","url":null,"abstract":"Institute 1 Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Leipzig, Deutschland 2 Klinik für Nuklearmedizin, Medizinische Hochschule Hannover, Deutschland 3 Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Deutschland 4 Klinik und Poliklinik für Nuklearmedizin, Universitätsmedizin Rostock, Deutschland 5 Nuklearmedizinische Klinik, Universitätsklinikum Erlangen, Deutschland 6 Klinik für Nuklearmedizin, Universitätsklinikum Münster, Deutschland 7 Klinik für Nuklearmedizin, Kliniken Mariahilf, Mönchengladbach, Deutschland 8 Klinik und Poliklinik für Nuklearmedizin, Universitätsmedizin Mainz, Deutschland 9 Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar, München, Deutschland 10 Klinik für Nuklearmedizin, Universitätsklinikum Essen, Deutschland Bibliografie Nuklearmedizin 2021; 60: 262–263 DOI 10.1055/a-1489-0375 ISSN 0029-5566 © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"60 4","pages":"262-263"},"PeriodicalIF":1.5,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39257573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: Breast metastasis in a prostate cancer patient.","authors":"Bilêl Habacha,&nbsp;Ralph Alexander Bundschuh,&nbsp;Florian C Gärtner,&nbsp;Jan-Frederic Lau,&nbsp;Yon-Dschun Ko,&nbsp;Glen Kristiansen,&nbsp;Markus Essler","doi":"10.1055/a-1310-3633","DOIUrl":"https://doi.org/10.1055/a-1310-3633","url":null,"abstract":"At the age of 63, the patient was first diagnosed with prostate cancer, initial stage pT2a, pN0, cM1, Gleason score 4 + 3 = 7, iPSA 8.8 ng/ml. Staging with magnetic resonance imaging (MRI) of the pelvis indicated extended local tumor including infiltration of the bladder, no suspicious lymph nodes were found. A radical prostatovesiculoectomy was performed. 5 years later, a local recurrence occurred, after which salvage radiotherapy of the prostate bed was carried out. This was followed by another local recurrence 8 years later with bladder floor infiltration, leading to surgical resection of the bladder (cystectomy) and the creation of an ilium conduit for urinary diversion (stage of relapse: pT4, cN0, M1, R1, L0, V0, Gleason 5 + 5 = 10). 3 years later there was an increasingly progressive course with disseminated bone metastases and a recurrent local relapse in the prostate bed. In the same year, irradiation of the bone metastases and taxane-containing chemotherapy (3 cycles Docetaxel) were performed for palliation. Due to subsequent further morphological disease progression, increasing PSA and aggravation of pain, we opted for radionuclide therapy with Lutetium-177-PSMA as compassionate use due to the lack of other therapy options. Before Lutetium-177PSMA therapy, Gallium-68-PSMA PET/CT was carried out showing intense expression in local recurrence, multiple bone metastases in the whole skeletal system as well as in pelvic and retroperitoneal lymph nodes classified as PSMA-RADS 5 according to [1]. In addition, the PET/CT examination showed intense expression of PSMA in a mass in the left breast (▶ Fig. 1). As initially, breast cancer was suspected this lesion was classified as PSMA-RADS 3C. However, a breast biopsy under local anesthesia with histological evaluation did not confirm this suspicion. Surprisingly, the histological examination revealed metastases from prostate cancer in the left breast (▶ Fig. 2). Subsequently, the first cycle of Lutetium-177-PSMA therapy was performed. Prophylactic cooling of the parotid glands was started 30 minutes before intravenous application of 6500 MBq Lu-177-PSMA, accompanied by 1000ml NaCl. One day after the application of Lutetium-177PSMA, intense activity accumulation in the metastasis in the left breast was observed in post-therapeutic whole-body scintigraphy (▶ Fig. 3). Overall, the therapy was tolerated well without side effects. After an inpatient stay of 3 days, the patient was discharged in reduced general condition. However, the patient died a few weeks later, thus further therapy cycles could not be continued and response could not be evaluated.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"60 4","pages":"302-303"},"PeriodicalIF":1.5,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25494251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Local recurrence of iodine refractory thyroid cancers. Surgical therapy options for larynx and trachea infiltration].","authors":"Heinrich Fuerst,&nbsp;Thomas Negele,&nbsp;Nikolaos Tsalos,&nbsp;Andreas Fertl,&nbsp;Markus Suckfüll,&nbsp;Andrei Todica,&nbsp;Peter Bartenstein","doi":"10.1055/a-1475-3638","DOIUrl":"https://doi.org/10.1055/a-1475-3638","url":null,"abstract":"<p><strong>Aim: </strong> Local recurrence of thyroid carcinomas can result in tumor infiltration in the lower region of the larynx. Since these tumors typically no longer store iodine, treatment options are greatly limited. The present study describes our experience with laryngo-tracheal resection of such cases of local recurrence.</p><p><strong>Materials and methods: </strong> From July 2019 to November 2020, we treated five patients with malignant infiltration of the trachea and larynx due to local recurrence of a thyroid carcinoma. We performed laryngo-tracheal resection with end-to-end anastomosis in four patients and frontolateral partial laryngectomy in one patient.</p><p><strong>Results: </strong> The median length of hospital stay was 6 days (5-14). An R0 resection was performed in two patients. Problems with the anastomosis or bilateral recurrent laryngeal nerve paralysis was not seen in any of the patients. One patient had to be reintubated on the second postoperative day due to lung failure. He was able to be extubated after five days.</p><p><strong>Conclusion: </strong> High tracheal resection with partial resection of the larynx was able to be performed with minimal risk. Although radical resections are rare, they expand oncological treatment options in the case of local recurrence of thyroid carcinomas that are iodine-refractory. High tracheal resection could be part of the oncological treatment spectrum in the case of local recurrence of thyroid carcinomas that no longer store iodine.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"60 4","pages":"272-277"},"PeriodicalIF":1.5,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39017799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}